World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
75
Citations
22655
World Ranking
19076
National Ranking
9509

C. Patrick Reynolds publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where C. Patrick Reynolds sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 278 publications — 13th percentile

13% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

C. Patrick Reynolds D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where C. Patrick Reynolds sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 75 D-Index — 6th percentile

6% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

C. Patrick Reynolds is affiliated with Texas Tech University Health Sciences Center in the United States. Their research spans multiple areas within medicine and molecular biology, focusing significantly on neuroblastoma and cancer biology. Reynolds has contributed extensively to the understanding of cancer mechanisms, telomere biology, and therapeutic resistance in cancer cells.

The scientist's main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these broad fields, Reynolds has concentrated research efforts on the following subfields:

  • Molecular Biology
  • Neurology
  • Oncology
  • Cancer Research
  • Ophthalmology

Key topics investigated by Reynolds cover a range of cancer-related areas:

  • Neuroblastoma Research and Treatments
  • Cancer, Hypoxia, and Metabolism
  • Cancer therapeutics and mechanisms
  • Telomeres, Telomerase, and Senescence
  • Cell death mechanisms and regulation
  • Glioma Diagnosis and Treatment
  • Cancer-related Molecular Pathways

Recent notable publications authored or co-authored by Reynolds include:

  • "Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma" (2020, Cancer Research)
  • "ALT neuroblastoma chemoresistance due to telomere dysfunction-induced ATM activation is reversible with ATM inhibitor AZD0156" (2021, Science Translational Medicine)
  • "MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma" (2020, Cell Death and Disease)
  • "Reduced ER-mitochondria connectivity promotes neuroblastoma multidrug resistance" (2022, The EMBO Journal)
  • "Alternative Lengthening of Telomeres in Cancer Confers a Vulnerability to Reactivation of p53 Function" (2022, Cancer Research)

Reynolds frequently publishes in a select group of venues, reflecting their focus on oncology and clinical research:

  • Cancer Research
  • Journal of Clinical Oncology
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Science Translational Medicine
  • Cancer Chemotherapy and Pharmacology

The scientist has collaborated regularly with multiple co-authors, suggesting ongoing partnerships in their research work. Frequent collaborators include:

  • Balakrishna Koneru
  • Min H. Kang
  • Trevor A. Burrow
  • Ashly Hindle
  • Thinh H. Nguyen

Best Publications

  • Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

    Alice L. Yu;Andrew L. Gilman;M. Fevzi Ozkaynak;Wendy B. London

  • Determination of subcutaneous tumor size in athymic (nude) mice

    Mary M. Tomayko;C. Patrick Reynolds

  • Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy.

    Min H. Kang;C. Patrick Reynolds

  • Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study

    Katherine K. Matthay;C. Patrick Reynolds;Robert C. Seeger;Hiroyuki Shimada

  • The pediatric preclinical testing program: description of models and early testing results.

    Peter J. Houghton;Christopher L. Morton;Chandra Tucker;Debbie Payne

  • Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma.

    Mark Sausen;Rebecca J Leary;Siân Jones;Siân Jones;Jian Wu;Jian Wu

  • Ceramide synthesis and metabolism as a target for cancer therapy.

    C.Patrick Reynolds;Barry J. Maurer;Richard N. Kolesnick

  • Retinoid therapy of high-risk neuroblastoma.

    C.Patrick Reynolds;Katherine K. Matthay;Judith G. Villablanca;Barry J. Maurer

  • Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma

    David L. Baker;Mary L. Schmidt;Susan L. Cohn;John M. Maris

  • The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA

    Philipp Kapranov;Georges St Laurent;Georges St Laurent;Tal Raz;Fatih Ozsolak

  • Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study

    Suzanne S. Shusterman;Wendy B. London;Stephen D. Gillies;Jacquelyn A. Hank

  • Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial

    Susan G Kreissman;Robert C Seeger;Katherine K Matthay;Wendy B London;Wendy B London

  • Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)

    John M. Maris;John M. Maris;Christopher L. Morton;Richard Gorlick;E. Anders Kolb

  • Synergistic Cytotoxicity in Solid Tumor Cell Lines Between N-(4-Hydroxyphenyl)retinamide and Modulators of Ceramide Metabolism

    Barry J. Maurer;Lisa Melton;Carolyn Billups;Myles C. Cabot

  • E-Cadherin Cell-Cell Adhesion in Ewing Tumor Cells Mediates Suppression of Anoikis through Activation of the ErbB4 Tyrosine Kinase

    Hyung-Gyoo Kang;Jasmine M. Jenabi;Jingsong Zhang;Nino Keshelava

  • A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children’s Oncology Group

    Kaci L. Osenga;Jacquelyn A. Hank;Mark R. Albertini;Jacek Gan

  • Outcome After Surgery Alone or With Restricted Use of Chemotherapy for Patients With Low-Risk Neuroblastoma: Results of Children's Oncology Group Study P9641

    Douglas R. Strother;Wendy B. London;Mary Lou Schmidt;Garrett M. Brodeur

  • Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program.

    E. Anders Kolb;E. Anders Kolb;Richard Gorlick;Peter J. Houghton;Christopher L. Morton

  • Phase I Dose Escalation of Iodine-131–Metaiodobenzylguanidine With Myeloablative Chemotherapy and Autologous Stem-Cell Transplantation in Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Consortium Study

    Katherine K. Matthay;Jessica C. Tan;Judith G. Villablanca;Gregory A. Yanik

  • Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.

    Peter J. Houghton;Christopher L. Morton;E. Anders Kolb;Richard Gorlick

Frequent Co-Authors

John M. Maris
John M. Maris Children's Hospital of Philadelphia
Malcolm A. Smith
Malcolm A. Smith National Institutes of Health
Peter J. Houghton
Peter J. Houghton The University of Texas Health Science Center at San Antonio
Richard Gorlick
Richard Gorlick The University of Texas MD Anderson Cancer Center
Robert C. Seeger
Robert C. Seeger Children's Hospital of Los Angeles
Timothy J. Triche
Timothy J. Triche Van Andel Institute
Katherine K. Matthay
Katherine K. Matthay University of California, San Francisco
Susan Groshen
Susan Groshen University of Southern California
Hiroyuki Shimada
Hiroyuki Shimada Stanford University
Wendy B. London
Wendy B. London Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative career pathways in healthcare can expand your options beyond traditional medical school. For those looking to enter the workforce quickly, accelerated lpn programs offer a fast and flexible entry point into nursing, equipping you with hands-on patient care experience in as little as a year.

If mental health interests you, there are accelerated msn psychiatric np programs available online. These programs let registered nurses move quickly into advanced practice roles focused on psychiatric and mental health care—an area with growing demand.

There’s also strong demand for leadership in the healthcare sector. Earning a healthcare administration degree online can prepare you for administrative and management roles, influencing how care is delivered across health systems.

For further career advancement, consider the options for a master’s in this field. Find programs with a manageable investment by comparing masters in healthcare administration cost to optimize both your education and financial planning.

Best Scientists Citing C. Patrick Reynolds

Trending Scientists

Recently Published Articles